Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2017-07-10 Capital/Financing Update
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
2017.07.10 CP GENFIT Bilan semestriel contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its primary subject is announcing the "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE" (Semi-annual review of the liquidity contract) with CIC, detailing the number of shares and cash held as of June 30, 2017. This is a routine disclosure related to market making/liquidity arrangements, not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). Since it is a specific regulatory/market-related announcement that doesn't fit perfectly into the other specific categories (like DIRS, DIV, CAP), it falls best under the general regulatory announcement category, RNS, as it is a formal communication to the market about a specific arrangement. Given the short length (3875 chars) and the nature of the announcement (reporting on a contract status), it is not the full report itself. It is a specific market update. While it relates to capital structure indirectly, it is primarily a disclosure about the liquidity agreement. RNS (Regulatory Filings) is the most appropriate fallback for specific, non-core financial disclosures that are mandatory or routine.
2017-07-10 French
2017.07.10 PR GENFIT Half year report of liquidity contract
Capital/Financing Update Classification · 99% confidence The document is titled "PRESS RELEASE" and specifically announces the "HALF-YEAR REPORT OF LIQUIDITY CONTRACT WITH CIC". It details the holdings in the liquidity account as of June 30, 2017, comparing them to the previous report date (December 31, 2016). This is a periodic disclosure related to financial operations (liquidity management) but is presented as a press release, not a comprehensive financial report (like 10-K or IR). Since it is a specific, periodic financial disclosure that doesn't fit the definitions for ER (Earnings Release), IR (Interim Report), or NAV (Net Asset Value), and it is a formal announcement, it best fits the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially a specialized financial update. Given the specific nature of reporting on a liquidity contract, it is a regulatory disclosure. Since there is no specific code for 'Liquidity Contract Report', RNS (Regulatory Filings) serves as the most appropriate fallback for a formal, non-standard regulatory announcement. However, upon reviewing the definitions, the content is a specific financial update regarding capital/financing activities (liquidity contract). While not a direct fundraising announcement (CAP), it relates to the company's financial structure maintenance. Given its brevity and press release format, RNS is the safest general regulatory classification, but let's re-evaluate against CAP (Capital/Financing Update). Liquidity contracts are often related to share stabilization/financing mechanisms. Since it is a formal report on a financial mechanism, RNS is the most accurate catch-all for non-standard disclosures.
2017-07-10 English
2017.06.23 PR GENFIT BM IVD
Regulatory Filings Classification · 95% confidence The document is a press release dated June 23, 2017, announcing scientific and development milestones for GENFIT's NASH diagnostic test. It details the completion of a feasibility phase, validation of biomarkers using data from the Phase 3 RESOLVE-IT trial, and plans for the next industrial development phase, including regulatory strategy (FDA/CE-marking) and potential partnerships. This content structure—announcing key progress, providing data tables, and including forward-looking statements—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on operational and scientific progress rather than just summarizing quarterly financial figures (which would be ER) or providing a comprehensive annual review (10-K), it fits best as an Earnings Release (ER) or a general announcement. Given the focus on scientific milestones and development progress rather than just financial results, and since it is not a transcript (CT), presentation (IP), or formal regulatory filing like 10-K, ER is the most appropriate fit for a significant corporate update announcing progress that often accompanies financial reporting periods, even if specific P&L numbers are absent. However, because it is a detailed announcement of scientific progress and future plans, it strongly resembles an Investor Presentation (IP) in content depth, but it is structured as a press release. Given the options, and recognizing it is a formal announcement of operational progress, ER is often used for such updates. If it were purely a presentation deck, IP would be chosen. Since it is a press release detailing progress, ER is the closest fit among the provided options for a non-financial-statement-heavy update.
2017-06-23 English
2017.06.23 CP GENFIT BM IVD
Regulatory Filings Classification · 95% confidence The document is a press release dated June 23, 2017, announcing a significant milestone in GENFIT's diagnostic program for NASH (Non-alcoholic steatohepatitis). It details the successful completion of a feasibility phase, confirmation of biomarker performance using data from the Phase 3 RESOLVE-IT study, and the launch of the industrial development phase for an In-Vitro Diagnostic (IVD) test. It includes scientific data (a table comparing diagnostic scores), quotes from experts, and outlines future regulatory and partnership plans. This content structure—a formal announcement of business/scientific progress, often including key data summaries and forward-looking statements—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on scientific/development progress rather than quarterly financial results (which would typically be an ER or IR), and it is not a transcript (CT), a formal annual report (10-K), or a proxy statement (DEF 14A), it best fits the category for initial announcements of key operational/scientific progress. Given the focus on announcing results and moving to the next development stage, 'Earnings Release' (ER) is often used broadly for major operational updates in biotech/pharma, but 'Investor Presentation' (IP) or 'Regulatory Filings' (RNS) are also possibilities. However, the format is a standard press release announcing a major operational/scientific achievement, which often overlaps with the function of an Earnings Release (ER) in providing key performance indicators/milestones, or sometimes an Investor Presentation (IP) if it were structured as slides. Since it is a formal press release announcing key progress and data validation, and it is not explicitly a presentation (IP) or a regulatory filing announcement (RPA/RNS), it aligns most closely with the function of an 'Earnings Release' (ER) as a primary announcement of period performance/milestones, even if the period is scientific rather than strictly fiscal. Given the context of major scientific validation and moving to the next phase, it is a significant corporate announcement. If a more specific category existed for 'Scientific/R&D Milestone Announcement', that would be ideal. Lacking that, ER is the closest fit for a major, time-sensitive corporate announcement of results/progress.
2017-06-23 French
2017.06.16 PR GENFIT Outcome of Shareholders' Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is explicitly titled "PRESS RELEASE" and announces the "OUTCOME OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF JUNE 16, 2017." It details the approval of resolutions, the nomination of the Chairman and CEO, and the composition of Board committees. This content directly relates to the results of a shareholder meeting and subsequent governance changes. While it touches upon management appointments (MANG), the primary focus is reporting the official results of the meeting itself. The most specific category for reporting official results from a general meeting is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not an AGM presentation (AGM-R), nor is it a general governance report (CGR) or a management change announcement (MANG), as it is specifically about the meeting's outcome.
2017-06-16 English
2017.06.16 CP GENFIT Résultats AGM
AGM Information Classification · 98% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and details the results of the "ASSEMBLEE GENERALE ORDINAIRE ET EXTRAORDINAIRE" (Ordinary and Extraordinary General Meeting) held on June 16, 2017. It specifically mentions the approval of resolutions, voting results (quorum), and the subsequent appointment of the Chairman and Board Committees. This content directly relates to the outcomes and proceedings of a shareholder meeting. The most appropriate category is AGM-R (AGM Information), as it reports on the results and key decisions made during the Annual General Meeting.
2017-06-16 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.